Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of efficacy and safety of Zytux (rituximab) in refractory myasthenia gravis
IRCT20150303021315N18Phase 4Completed
- Sponsor
- AryoGen Biopharma
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rituximab in myasthenia gravis (MG), sponsored by AryoGen Biopharma. Started Feb 2020; status: completed.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on IRCT20150303021315N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N18.